Skip to NavigationSkip to content

cancer treatment

Astellas prostate cancer drug gets third approval from MHRA

MHRA sign

The MHRA has approved Astellas Pharma’s XTANDI (enzalutamide) drug for the treatment of a third form of prostate cancer, making it the only oral therapy approved by the agency for three different types of the illness.

NICE rejects Merck Serono’s Bavencio for urothelial cancer

NICE building in London

The use of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy is not recommended by NICE following an announcement on May 6.

Merck kidney and uterus cancer treatments granted priority review by FDA

Merck sign

The FDA has granted priority review for Merck (MSD) and Eisai’s application for two new approvals for the combination of Merck’s KEYTRUDA and Eisai’s LENVIMA for the treatment of certain kidney and uterus cancers. 

Researchers find possible new treatment for several cancers

Research in a lab
Image credit: Shutterstock

Researchers at The Institute of Cancer Research (ICR) in London have discovered a new use for an ovarian and breast cancer drug that could make it effective against multiple other cancers, including a common form of kidney cancer.

Amgen stomach cancer drug awarded Breakthrough Therapy Designation

Amgen flag

Amgen’s investigational therapy, bemarituzumab, for certain types of stomach and esophagus cancer, has been granted Breakthrough Therapy Designation by the FDA.

Exscientia enter first-ever AI cancer drug into Phase I trials

Cancer cell

Exscientia and Evotec have announced that they are entering an AI-designed immuno-oncology drug into Phase I trials for the first time ever.

Takeda acquire Maverick in $525m deal to expand cancer therapy portfolio

Takeda building

Takeda has acquired Maverick Therapeutics in a deal worth up to $525 million, in order to expand its portfolio of novel immuno-oncology treatments, and advance its existing T-cell therapies.

Merck and Debiopharm agree €898m deal to develop head and neck cancer treatments

Merck building

German science and technology company Merck have agreed a worldwide in-licensing agreement with Debiopharm for the development and commercialisation of xevinapant, a treatment currently being trialled for advanced squamous cell carcinoma of the head and neck.

ONK and Anthony Nolan combine forces to work on blood cancer therapies

blood samples in test tubes

ONK Therapeutics and blood cancer charity Anthony Nolan will work together on therapies for patients with haematological malignancies (blood cancers) and solid tumours.

New Cell Guidance technology has potential to help treat cancer

Cell Guidance Systems’ new POlyhedrin Delivery System (PODS) technology has been shown to have therapeutic potential in the treatment of cancer and other diseases, the company announced today.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches